The financial impact of cancer care on renal cancer patients
Doreen A. Ezeife1, Brendon Josh Morganstein2, Steven Yip1, Malcolm Ryan2, Jennifer H. Law2, Amy Yimin Guan3, Lisa W. Le3, Aaron R. Hansen2, Adrian Sacher2, Georg A. Bjarnason4, Mark K. Doherty4, Natasha B. Leighl2
Canadian Journal of Urology, Vol.28, No.4, pp. 10762-10767, 2021
Abstract Introduction: Advances in novel treatment options may render renal cell cancer (RCC) patients susceptible to the financial toxicity (FT) of cancer treatment, and the factors associated with FT are unknown.
Materials and methods: Eligible patients were ≥ 18 years old and had a diagnosis of stage IV RCC for at least 3 months. Patients were recruited from Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre (Toronto, Canada). FT was assessed using the validated Comprehensive Score for Financial Toxicity (COST) instrument, a 12-question survey scored from 0-44, with lower scores reflecting worse FT. Patient and treatment characteristics,… More >